Legato Capital Management LLC Invests $805,000 in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Legato Capital Management LLC purchased a new stake in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 103,187 shares of the company’s stock, valued at approximately $805,000.

Several other institutional investors and hedge funds have also modified their holdings of the business. GSA Capital Partners LLP bought a new position in GoodRx during the first quarter valued at about $1,638,000. Rubric Capital Management LP bought a new position in shares of GoodRx in the 4th quarter valued at approximately $39,348,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in GoodRx by 61.1% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 181,512 shares of the company’s stock worth $1,289,000 after purchasing an additional 68,835 shares during the last quarter. Jupiter Asset Management Ltd. acquired a new stake in GoodRx in the 1st quarter worth approximately $707,000. Finally, ClariVest Asset Management LLC bought a new stake in GoodRx during the first quarter worth approximately $1,091,000. Institutional investors and hedge funds own 63.77% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on GDRX shares. Citigroup reduced their price objective on shares of GoodRx from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Friday, August 9th. UBS Group decreased their price target on shares of GoodRx from $9.00 to $8.50 and set a “neutral” rating for the company in a report on Friday, August 9th. Barclays lifted their price objective on GoodRx from $9.00 to $10.00 and gave the stock an “overweight” rating in a research note on Monday, May 20th. TD Cowen raised their target price on GoodRx from $14.00 to $16.00 and gave the company a “buy” rating in a report on Thursday, May 16th. Finally, Raymond James raised GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 price target on the stock in a research report on Friday, August 9th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $9.36.

GoodRx Trading Up 5.4 %

Shares of GoodRx stock opened at $8.59 on Wednesday. GoodRx Holdings, Inc. has a 52-week low of $4.14 and a 52-week high of $9.26. The firm has a market capitalization of $3.22 billion, a PE ratio of -859.00, a price-to-earnings-growth ratio of 4.08 and a beta of 1.39. The company has a debt-to-equity ratio of 1.02, a current ratio of 6.29 and a quick ratio of 6.29. The company’s fifty day moving average price is $8.02 and its two-hundred day moving average price is $7.49.

GoodRx (NASDAQ:GDRX) last issued its earnings results on Thursday, August 8th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.01). GoodRx had a negative net margin of 0.86% and a positive return on equity of 3.45%. The business had revenue of $200.60 million for the quarter, compared to analyst estimates of $200.47 million. During the same quarter last year, the firm posted $0.02 earnings per share. GoodRx’s revenue was up 5.7% on a year-over-year basis. On average, analysts expect that GoodRx Holdings, Inc. will post 0.17 EPS for the current year.

GoodRx Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.